<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: SEPTEMBER 30, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From __________ to __________.
Commission File Number: 0-27120
KENSEY NASH CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 36-3316412
(State or other jurisdiction (IRS Employer Identification No.)
of incorporation or organization)
MARSH CREEK CORPORATE CENTER, 55 EAST UWCHLAN AVENUE, SUITE 204, EXTON,
PENNSYLVANIA 19341
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (610) 524-0188
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
As of October 31, 1998, there were outstanding 7,459,272 shares of Common
Stock, par value $.001, of the registrant.
1
<PAGE> 2
KENSEY NASH CORPORATION
QUARTER ENDED SEPTEMBER 30, 1998
INDEX
<TABLE>
<CAPTION>
PAGE
----
PART I - FINANCIAL INFORMATION
<S> <C>
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets
as of September 30, 1998 (Unaudited) and June 30, 1998 ....................... 3
Condensed Consolidated Statements of Operations
for the three months ended September 30, 1998 and 1997 (Unaudited) ............ 4
Condensed Consolidated Statements of Stockholders' Equity as of
September 30, 1998 (Unaudited) and June 30, 1998 .............................. 5
Condensed Consolidated Statements of Cash Flows
for the three months ended September 30, 1998 and 1997 (Unaudited) ............ 6
Notes to Condensed Consolidated Financial Statements (Unaudited) ............... 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS .................................. 9
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K ................................................... 13
SIGNATURES ....................................................................................... 14
</TABLE>
2
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
- - -------------------------------------------------------------------------------------------------------------------------------
SEPTEMBER 30, JUNE 30,
ASSETS 1998 1998
CURRENT ASSETS: (Unaudited)
<S> <C> <C>
Cash and cash equivalents $ 537,055 $ 1,407,684
Short-term investments 6,206,386 6,368,866
Trade receivables 2,006,103 1,369,960
Royalties receivable (Note 2) 721,967 645,784
Other receivables (including approximately $66,000 and $59,000 at
September 30, 1998 and June 30, 1998, respectively, due from employees) 369,760 225,424
Inventory (Note 3) 844,363 1,027,326
Prepaid expenses and other 313,545 200,169
------------ ------------
Total current assets 10,999,179 11,245,213
------------ ------------
PROPERTY, PLANT AND EQUIPMENT, AT COST:
Leasehold improvements 4,009,064 4,006,066
Machinery, furniture and equipment 3,843,645 3,599,827
Construction in progress 207,160 191,154
------------ ------------
Total property, plant and equipment 8,059,869 7,797,047
Accumulated depreciation (3,088,070) (2,843,785)
------------ ------------
Net property, plant and equipment 4,971,799 4,953,262
------------ ------------
OTHER ASSETS:
Restricted investments (Note 4) 1,914,418 1,914,418
Property under capital leases, net 52,544 61,181
Acquired patents, net of accumulated amortization of $190,937 and $127,291
at September 30, 1998 and June 30, 1998, respectively 3,801,472 3,865,118
------------ ------------
Total other assets 5,768,434 5,840,717
------------ ------------
TOTAL $ 21,739,412 $ 22,039,192
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 791,370 $ 639,605
Accrued expenses 552,375 551,573
Current portion of line of credit, obligation under patent acquisition agreement
and capital lease obligations 638,379 577,891
Deferred revenue 48,700 53,120
------------ ------------
Total current liabilities 2,030,824 1,822,189
------------ ------------
DEFERRED REVENUE - ROYALTIES (Note 2) 1,276,874 1,979,580
LINE OF CREDIT, OBLIGATION UNDER PATENT ACQUISITION AGREEMENT
and OBLIGATION UNDER CAPITAL LEASES, long-term portion 2,197,672 2,373,960
------------ ------------
Total liabilities 5,505,370 6,175,729
------------ ------------
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value, 100,000 shares authorized,
no shares issued or outstanding at September 30, 1998 and June 30, 1998
Common stock, $.001 par value, 25,000,000 shares authorized,
7,459,272 shares issued and outstanding at September 30, 1998
and June 30, 1998 7,459 7,459
Capital in excess of par value 37,597,381 37,597,381
Accumulated deficit (21,370,798) (21,741,377)
------------ ------------
Total stockholders' equity 16,234,042 15,863,463
------------ ------------
TOTAL $ 21,739,412 $ 22,039,192
============ ============
</TABLE>
See notes to condensed consolidated financial statements.
3
<PAGE> 4
<TABLE>
<CAPTION>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
- - --------------------------------------------------------------------------------------
THREE MONTHS ENDED
SEPTEMBER 30,
-----------------------------------
1998 1997
<S> <C> <C>
REVENUES (Notes 1 and 2):
Net sales $ 1,376,978 $ 534,061
Research and development 769,108 733,331
Royalty income 1,405,411 297,898
------------- -------------
Total revenues 3,551,497 1,565,290
------------- -------------
OPERATING COSTS AND EXPENSES:
Cost of products sold 1,278,373 816,090
Research and development 1,397,771 1,185,385
Selling, general and administrative 573,529 364,217
------------- -------------
Total operating costs and expenses 3,249,673 2,365,692
------------- -------------
INCOME (LOSS) FROM OPERATIONS 301,824 (800,402)
------------- -------------
OTHER INCOME:
Interest income 134,713 133,665
Interest expense (65,959) (14,584)
Other 1 1,641
------------- -------------
Total other income - net 68,755 120,722
------------- -------------
INCOME (LOSS) BEFORE INCOME TAXES 370,579 (679,680)
Provision for Income Taxes (Note 5)
------------- -------------
NET INCOME (LOSS) $ 370,579 $ (679,680)
============= =============
EARNINGS (LOSS) PER COMMON SHARE and
EARNINGS (LOSS) PER COMMON SHARE - $ 0.05 $ (0.09)
============= =============
assuming dilution (Note 1)
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING (Note 1) 7,465,754 7,205,400
============= =============
</TABLE>
See notes to condensed consolidated financial statements.
4
<PAGE> 5
<TABLE>
<CAPTION>
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
- - ----------------------------------------------------------------------------------------------------------------------------------
CAPITAL
COMMON STOCK IN EXCESS
-------------------------- OF PAR ACCUMULATED
SHARES AMOUNT VALUE DEFICIT TOTAL
<S> <C> <C> <C> <C> <C>
BALANCE, JUNE 30, 1997 7,198,251 $ 7,198 $ 34,203,807 $ (22,084,059) $ 12,126,946
Exercise of stock options 61,021 61 556,174 556,235
Shares issued under Patent Acquisition
Agreement 200,000 200 2,837,400 2,837,600
Net income 342,682 342,682
----------- -------- ------------- --------------- -------------
BALANCE, JUNE 30, 1998 7,459,272 7,459 37,597,381 (21,741,377) 15,863,463
Net income 370,579 370,579
----------- -------- ------------- --------------- -------------
BALANCE, SEPTEMBER 30, 1998 (Unaudited) 7,459,272 $ 7,459 $ 37,597,381 $ (21,370,798) $ 16,234,042
=========== ======== ============= =============== =============
</TABLE>
See notes to condensed consolidated financial statements.
5
<PAGE> 6
<TABLE>
<CAPTION>
KENSEY NASH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
- - ---------------------------------------------------------------------------------------------------------------------
THREE MONTHS ENDED
SEPTEMBER 30,
------------------------------
1998 1997
<S> <C> <C>
OPERATING ACTIVITIES:
Net income (loss) $ 370,579 $ (679,680)
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities:
Depreciation and amortization 316,568 210,577
Changes in assets and liabilities which used cash:
Accounts receivable (856,662) 453,842
Prepaid expenses and other current assets (113,376) (63,300)
Inventory 182,963 (88,584)
Accounts payable and accrued expenses 152,567 (415,538)
Deferred revenue (707,126) (70,432)
----------- -----------
Net cash used in operating activities (654,487) (653,115)
----------- -----------
INVESTING ACTIVITIES:
Additions to property, plant and equipment (262,822) (145,456)
Sale of investments 162,480 2,819,550
----------- -----------
Net cash (used in) provided by investing activities (100,342) 2,674,094
----------- -----------
FINANCING ACTIVITIES:
Principal payments under capital leases (9,483) (12,174)
Repayments of patent acquisition obligation (106,317)
Exercise of stock options 152,290
----------- -----------
Net cash (used in) provided by financing activities (115,800) 140,116
----------- -----------
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (870,629) 2,161,095
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 1,407,684 868,180
----------- -----------
CASH AND CASH EQUIVALENTS, END OF YEAR $ 537,055 $ 3,029,275
=========== ===========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest $ 65,959 $ 14,584
=========== ===========
Cash paid for income taxes $ $
=========== ===========
</TABLE>
See notes to condensed consolidated financial statements.
6
<PAGE> 7
KENSEY NASH CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 -- CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BASIS OF PRESENTATION
The condensed consolidated balance sheet at June 30, 1998 and the
condensed consolidated statement of stockholders' equity at June 30,
1998 have been condensed from the audited financial statements at that
date. The condensed consolidated balance sheet at September 30, 1998,
the condensed consolidated statements of operations for the three months
ended September 30, 1998 and 1997 and the condensed consolidated
statements of cash flows for the three months ended September 30, 1998
and 1997 have been prepared by Kensey Nash Corporation (the "Company")
and have not been audited by the Company's Independent Auditors. In the
opinion of management, all adjustments (which include only normal
recurring adjustments) necessary to present fairly the financial
position, results of operations and cash flows at September 30, 1998 and
for all periods presented have been made.
Certain information and note disclosures normally included in the
Company's annual financial statements prepared in accordance with
generally accepted accounting principles have been condensed or omitted.
These condensed consolidated financial statements should be read in
conjunction with the financial statements and notes thereto included in
the Company's June 30, 1998 consolidated financial statements filed with
the Securities and Exchange Commission on Form 10-K. The results of
operations for the period ended September 30, 1998 are not necessarily
indicative of operating results for the full year.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents represent cash in banks and short-term
investments having an original maturity of less than three months.
EXPORT SALES
Export sales from the Company's U.S. operations to unaffiliated
customers in Europe totaled $29,910 and $22,485 for the three months
ended September 30, 1998 and 1997, respectively.
EARNINGS PER SHARE
Earnings per share are calculated in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 128, Earnings per Share,
which requires the Company to report both basic and diluted earnings per
share ("EPS"). Basic and diluted EPS are computed using the weighted
average number of shares of common stock outstanding, with common
equivalent shares from options included in the diluted computation when
their effect is dilutive. All previously disclosed earnings per share
data have been recalculated to reflect the provisions of SFAS No. 128.
NOTE 2 -- DEFERRED REVENUE - ROYALTIES
Upon receipt of pre-market approval for the 8 French ("F") size
Angio-Seal device (the "Angio-Seal") from the Food and Drug
Administration (the "FDA") on September 30, 1996, the Company received a
$3 million advance on future royalties under the Company's licensing
agreement (the "Licensing Agreement") with its Strategic Alliance
Partner. Such advance has been recorded as deferred revenue. The
Licensing Agreement provides for certain minimum royalty payments
("Minimum Royalty") during the first five years after receiving FDA
approval (each royalty year begins on October 1 and ends on September
30). As stipulated in the Licensing Agreement, the $3 million advance
will be reduced in each period by 50% of royalties earned in excess of
the Minimum Royalty in any royalty year. The remainder of royalties
earned will be received as cash proceeds by the Company. At September
30, 1998, the Company had
7
<PAGE> 8
exceeded the first and second royalty year (periods ended September 30,
1997 and September 30, 1998) Minimum Royalties by $352,310 and
$3,093,942, respectively. The deferred revenue balance has been reduced
by 50% of such total excess, to $1,276,874. As the Company cannot
reasonably estimate the excess, if any, of future royalty payments over
the Minimum Royalty in each year, the entire balance has been classified
as long-term at September 30, 1998.
NOTE 3 -- INVENTORY
Inventory is stated at the lower of cost (determined by the average cost
method which approximates first-in, first-out) or market. Inventory
primarily includes the cost of material utilized in the processing of the
Company's products and is as follows:
SEPTEMBER 30, JUNE 30,
1998 1998
------------- ----------
Raw materials $ 804,716 $ 971,357
Work in process 39,647 55,969
---------- ----------
Total $ 844,363 $1,027,326
========== ==========
NOTE 4 -- COMMITMENTS AND CONTINGENCIES
The Company has pledged $1,914,418 in investments as collateral to secure
certain bank loans to employees which were used by such employees for the
payment of taxes incurred by such employees as the result of the receipt of
Common Stock in settlement of the employee stock rights. In exchange for
the Company pledging collateral for such loans, each affected employee has
pledged their Common Stock as collateral to the Company. The balance
outstanding on such employee loans was $1,784,525 at September 30, 1998.
NOTE 5 -- INCOME TAXES
As of June 30, 1998, the Company had net operating loss carryforwards for
federal and state tax purposes totaling $18.0 and $2.8 million,
respectively. As such, no provision has been made for income taxes for the
three months ended September 30, 1998. A portion of the NOL may be subject
to various statutory limitations as to its usage.
8
<PAGE> 9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
The Company is a medical device company which has established three
technology platforms; puncture closure (the Angio-Seal), biomaterials (collagen
and resorbable polymers) and revascularization (the Aegis Vortex System)
("AVS"). The Company's operations are focused on the commercialization and
continuing development of its proprietary principal product, the Angio-Seal
Product Line, the continued expansion of its capabilities in biomaterials, and
the development of its revascularization catheter system, the AVS.
The Angio-Seal is a device for the sealing of arterial punctures created
during diagnostic and therapeutic cardiovascular procedures such as angiography,
angioplasty, atherectomy and the placement of stents. The Company participates
in the puncture closure market primarily through its relationship with its
Strategic Alliance Partner, which generates royalty income, research and
development funding and sales revenue through the manufacture of clinical
devices and components for the Angio-Seal.
The Company has expanded its capabilities in absorbable biomaterials.
The Company is currently manufacturing collagen products for third
parties for use as delivery systems for various applications including bone
growth proteins, artificial skin for burn victims and drug delivery for products
in various stages of clinical trials. As a result of its absorbable polymer
capabilities, the Company has entered into the orthopedic marketplace as an OEM
supplier of specialized products.
The Company's revascularization platform has been established to address
a market opportunity in cardiology for the treatment of occluded saphenous vein
bypass grafts and in-stent restenosis. The Company is developing the AVS
utilizing its patent platform and in-house expertise to address these life
threatening medical conditions.
The following discussion and analysis should be read in conjunction with
the Consolidated Financial Statements and the notes thereto contained elsewhere
in this report.
THREE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO THREE MONTHS ENDED SEPTEMBER
30, 1997
Revenues for these periods consisted of net sales, research and
development revenue, and royalty income. Revenues increased 127% to $3,551,000
in the three months ended September 30, 1998 from $1,565,000 in the three months
ended September 30, 1997. Net sales of products increased
9
<PAGE> 10
158% to $1,377,000 from $534,000 for the three months ended September 30, 1998
and 1997, respectively. Research and development revenues increased 5% to
$769,000 from $733,000 for the three months ended September 30, 1998 and 1997,
respectively. The increase in net sales was mainly attributable to an increase
in Angio-Seal components sold to the Company's Strategic Alliance Partner, as a
result of increased demand in the U.S. and European markets, as well as the
Company initiating sales of commercial bioresorbable OEM products in the
orthopedic marketplace. The increase in research and development revenues
relates to increased activity in contract research and development from the
Company's Strategic Alliance Partner for the 6F and 10F clinical trial programs
and for additional sizes of and product enhancements to the Angio-Seal Product
Line.
Royalty income increased 372% to $1,405,000 from $298,000 in the three
months ended September 30, 1998 and 1997, respectively. Approximately 75,000
Angio-Seal units were sold to end-users in the quarter ending September 30, 1998
compared to 22,000 units sold in the quarter ending September 30, 1997. The
increase in royalty income reflected increased demand in the both the U.S. and
European markets versus the same quarter a year earlier as well as an increase
in total royalty per unit resulting from the Patent Acquisition Agreement. As
the Company and its Strategic Alliance Partner continue to increase production
and market the Angio-Seal in the United States and in Europe, the Company
expects royalty income to become an increasingly significant source of revenue.
Royalty rates are based on volume of units sold and are comparable in both the
domestic and foreign licensing agreements with the Company's Strategic Alliance
Partner.
Cost of products sold increased 57% to $1,278,000 in the three months
ended September 30, 1998 from $816,000 in the three months ended September 30,
1997. This increase primarily reflects greater net sales of products offset by
favorable trends in gross margins.
Research and development expense, including regulatory and clinical
expense, increased 18% to $1,398,000 in the three months ended September 30,
1998 from $1,185,000 in the three months ended September 30, 1997. The Company
has expanded the development of additional Angio-Seal sizes and biomaterials
products, including resorbable polymers and collagen. In addition, the Company
has significantly expanded its development in revascularization technology
as it targets commencement of clinical trials on the AVS in the second half of
fiscal year 1999. The Company expects research and development expense to
continue at recent levels, if not slightly increase, as it continues development
of additional sizes of the Angio-Seal, investigates and develops new products,
conducts clinical trials and seeks regulatory approval for its products.
Selling, general and administrative expense increased 57% to $574,000 in
the three months ended September 30, 1998 from $364,000 in the three months
ended September 30, 1997. This increase was primarily a result of additional
legal expenses incurred due to the patent infringement suit against Perclose,
Inc. which was initiated in March 1998.
Interest expense increased 352% to $66,000 in the three months ended
September 30, 1998 from $15,000 in the three months ended September 30, 1997.
This increase was due to the Company's balance under the line of credit
increasing from $500,000 to $2,000,000 as well as interest charges recorded in
relation to the obligation under the Company's Patent Acquisition Agreement.
Interest income increased to $135,000 in the three months ended September 30,
1998 from $134,000 in the three months ended September 30, 1997. Total cash and
investment balances have remained consistent.
LIQUIDITY AND CAPITAL RESOURCES
Net cash used in the Company's operating activities during the three
months ended September 30, 1998 and 1997 was $654,000 and $653,000,
respectively. In the quarter ending September 30,
10
<PAGE> 11
1998, changes in asset and liabilities used $1,342,000 of cash, which was offset
by a net income of $371,000. In comparison, changes in asset and liabilities
used $184,000 and the Company had a net loss of $680,000 in the three months
ending September 30, 1997. Depreciation and amortization increased $106,000 in
the three months ended September 30, 1998 from the three months ended September
30, 1997.
Capital expenditures were $263,000 for the three months ended September
30, 1998, primarily representing leasehold improvements and machinery and
equipment related to the continued expansion of the Company's manufacturing
capabilities principally related to its collagen and polymer product lines.
The Company's cash, cash equivalents and short-term investments were
$6,743,000 at September 30, 1998. In addition, the Company has pledged
$1,914,000 in investments (not included in the $6,743,000) as collateral to
secure bank loans made to employees for the payment of taxes incurred by such
employees as a result of their receipt of Common Stock in settlement of the
employee stock rights at the time of the IPO. In exchange for the Company's
pledging this collateral, the employees have pledged their Common Stock as
collateral to the Company.
The Company has a $2,000,000 bank revolving line of credit that converts
to a term loan payable in 60 equal installments beginning January 1, 2000. The
Company received a $3,000,000 royalty advance under the License Agreement upon
receipt of FDA approval of the Angio-Seal in fiscal year 1997. This royalty
advance continues to be reduced as the Company exceeded minimum royalty
stipulations under the Licensing Agreement.
In November 1997, the Company acquired patents under a Patent
Acquisition Agreement in exchange for 200,000 shares of common stock and a
series of eight quarterly cash payments, beginning on March 31, 1998, totaling
$1.2 million. The patents have been recorded on the balance sheet at the value
of the shares on the date of the agreement plus the present value of the $1.2
million cash and any legal and other related costs incurred to acquire such
patents. The present value of the cash payments ($1.1 million) was recorded
between short and long-term liabilities at December 31, 1997 and reduced to
$773,000 upon payment of the third installment on September 30, 1998.
YEAR 2000 COMPLIANCE
The Company began work on the computer Year 2000 issue in fiscal year
1998 and expects to complete its efforts by the end of fiscal year 1999.
Software applications, hardware and related technologies have been, or are in
the process of being, upgraded or replaced to ensure that all systems are Year
2000 compliant. Replacing hardware or software in this fashion is considered a
normal cost of doing business and is being expensed or capitalized as
appropriate. The Company is also working with its significant suppliers and
customers to address any impact of their Year 2000 issues on the Company. The
Company does not warrant, however, that these companies' year 2000 compliance
activities will be completely successful. Management does not anticipate that
the costs of year 2000 compliance will have a material effect on the Company's
results of operations, cash flows, or financial position.
The Company anticipates that its results of operations will fluctuate
for the foreseeable future due to a number of factors. Such factors include the
Company's Strategic Alliance Partner's performance in the marketing,
manufacturing and distribution of the Angio-Seal Product Line, the timing of
future regulatory approvals in the United States and in countries outside of
Europe including Japan, the results of ongoing and planned clinical trials for
the Angio-Seal and other products, the acceptance of the Company's products in
the marketplace and competitive products generally and in particular those
designed for the sealing of arterial site punctures.
The Company plans to continue to expend substantial resources to fund
clinical trials to gain regulatory approvals and make additional marketing
claims and to continue to expand research and development activities for the
Angio-Seal, revascularization technology and biomaterials products.
The Company believes cash generated from operations as well as funds
available under financing arrangements with its bank will be sufficient to meet
the Company's operating and capital requirements for the next twelve months.
Statements contained in this Form 10-Q that are not historical facts are
forward-looking statements that are made pursuant to the Safe Harbor provisions
of the Private Securities Litigation Reform Act of 1995. The Company cautions
that a number of important factors could cause the Company's actual results for
fiscal 1999 and beyond to differ materially from those in any forward-looking
statements made by, or on behalf of, the Company. These important factors
include, without limitation, the time, effort and priority level that the
Company's Strategic Alliance Partner and its successors attach to the Angio-Seal
and the Strategic Alliance Partner's ability to successfully market
11
<PAGE> 12
and manufacture the Angio-Seal, the Company's ability to manufacture Angio-Seal
components, the results of ongoing clinical trials and timing of additional
regulatory approvals, announcements of technological innovations or the
introduction of new products by the Company or its competitors, competition by
rival developers of puncture closure devices, general business conditions in the
healthcare industry and general economic conditions. Results of operations in
any past period should not be considered indicative of the results to be
expected for future periods. Fluctuations in operating results may also result
in fluctuations in the price of the common stock.
12
<PAGE> 13
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
A. Exhibits.
None
B. Reports on Form 8-K.
None
C. Financial Data Schedule
13
<PAGE> 14
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KENSEY NASH CORPORATION
Date: November 16, 1998 By: /s/ Joseph W. Kaufmann
-------------------------------------
Joseph W. Kaufmann
President and Chief Executive Officer
14
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1999
<PERIOD-START> JUL-01-1998
<PERIOD-END> SEP-30-1998
<CASH> 537,055
<SECURITIES> 6,206,386
<RECEIVABLES> 3,097,830
<ALLOWANCES> 0
<INVENTORY> 844,363
<CURRENT-ASSETS> 10,999,179
<PP&E> 8,059,869
<DEPRECIATION> 3,088,070
<TOTAL-ASSETS> 21,739,412
<CURRENT-LIABILITIES> 2,030,824
<BONDS> 0
0
0
<COMMON> 7,459
<OTHER-SE> 16,226,583
<TOTAL-LIABILITY-AND-EQUITY> 21,739,412
<SALES> 1,376,978
<TOTAL-REVENUES> 3,551,497
<CGS> 1,278,373
<TOTAL-COSTS> 3,249,673
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 65,959
<INCOME-PRETAX> 370,579
<INCOME-TAX> 0
<INCOME-CONTINUING> 370,579
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 370,579
<EPS-PRIMARY> 0.05
<EPS-DILUTED> 0.05
</TABLE>
